Extrachromosomal DNA (ecDNA) amplification promotes intratumoral genetic heterogeneity and accelerated tumor evolution1,2,3; however, its frequency and clinical impact are unclear. Using computational analysis of whole-genome sequencing data from 3,212 cancer patients, we show that ecDNA amplification frequently occurs in most cancer types but not in blood or normal tissue. Oncogenes were highly enriched on amplified ecDNA, and the most common recurrent oncogene amplifications arose on ecDNA. EcDNA amplifications resulted in higher levels of oncogene transcription compared to copy number-matched linear DNA, coupled with enhanced chromatin accessibility, and more frequently resulted in transcript fusions. Patients whose cancers carried ecDNA had significantly shorter survival, even when controlled for tissue type, than patients whose cancers were not driven by ecDNA-based oncogene amplification. The results presented here demonstrate that ecDNA-based oncogene amplification is common in cancer, is different from chromosomal amplification and drives poor outcome for patients across many cancer types.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Information on accessing the data from the ICGC, including raw read files, can be found at https://docs.icgc.org/pcawg/data/. All open access TCGA data are publicly available through the National Cancer Institute Genomic Data Commons (https://gdc.cancer.gov/). The datasets marked ‘Controlled’ contain potentially identifiable information and require authorization from the ICGC and TCGA Data Access Committees. In accordance with the data access policies of the ICGC and TCGA projects, most molecular, clinical and specimen data are in an open tier that does not require access approval. To access sequencing data, researchers need to apply to the TCGA Data Access Committee via the database of Genotypes and Phenotypes (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset and to the ICGC Data Access Compliance Office (http://icgc.org/daco) for the ICGC portion. All images analyzed are available from figshare at https://figshare.com/s/6c3e2edc1ab299bb2fa0 and https://figshare.com/s/ab6a214738aa43833391.
AmpliconArchitect is available at https://github.com/virajbdeshpande/AmpliconArchitect. EcSeg is available at https://github.com/UCRajkumar/ecSeg.
deCarvalho, A. C. et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat. Genet. 50, 708–717 (2018).
Turner, K. M. et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543, 122–125 (2017).
Verhaak, R. G. W., Bafna, V. & Mischel, P. S. Extrachromosomal oncogene amplification in tumour pathogenesis and evolution. Nat. Rev. Cancer 19, 283–288 (2019).
Weischenfeldt, J. et al. Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat. Genet. 49, 65–74 (2017).
Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013).
Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010).
Alt, F. W., Kellems, R. E., Bertino, J. R. & Schimke, R. T. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol. Chem. 253, 1357–1370 (1978).
Kohl, N. E. et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 35, 359–367 (1983).
Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72–76 (2014).
Zheng, S. et al. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev. 27, 1462–1472 (2013).
Trask, B. J. Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. Trends Genet. 7, 149–154 (1991).
Deshpande, V. et al. Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. Nat. Commun. 10, 392 (2019).
Xu, K. et al. Structure and evolution of double minutes in diagnosis and relapse brain tumors. Acta Neuropathol. 137, 123–137 (2019).
Koche, R. P. et al. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. Nat. Genet. 52, 29–34 (2020).
Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
Zakov, S., Kinsella, M. & Bafna, V. An algorithmic approach for breakage-fusion-bridge detection in tumor genomes. Proc. Natl Acad. Sci. USA 110, 5546–5551 (2013).
Rajkumar, U. et al. EcSeg: semantic segmentation of metaphase images containing extrachromosomal DNA. iScience 21, 428–435 (2019).
Storlazzi, C. T. et al. Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res. 20, 1198–1206 (2010).
Møller, H. D., Parsons, L., Jørgensen, T. S., Botstein, D. & Regenberg, B. Extrachromosomal circular DNA is common in yeast. Proc. Natl Acad. Sci. USA 112, E3114–E3122 (2015).
Møller, H. D. et al. Circular DNA elements of chromosomal origin are common in healthy human somatic tissue. Nat. Commun. 9, 1069 (2018).
Kumar, P. et al. Normal and cancerous tissues release extrachromosomal circular DNA (eccDNA) into the circulation. Mol. Cancer Res. 15, 1197–1205 (2017).
Shibata, Y. et al. Extrachromosomal microDNAs and chromosomal microdeletions in normal tissues. Science 336, 82–86 (2012).
Davoli, T. & de Lange, T. The causes and consequences of polyploidy in normal development and cancer. Annu. Rev. Cell Dev. Biol. 27, 585–610 (2011).
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).
Cortés-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet. 52, 331–341 (2020).
Ly, P. et al. Chromosome segregation errors generate a diverse spectrum of simple and complex genomic rearrangements. Nat. Genet. 51, 705–715 (2019).
Zhang, C.-Z. et al. Chromothripsis from DNA damage in micronuclei. Nature 522, 179–184 (2015).
Umbreit, N. T. et al. Mechanisms generating cancer genome complexity from a single cell division error. Science 368, eaba0712 (2020).
Menghi, F. et al. The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. Cancer Cell 34, 197–210.e5 (2018).
Morton, A. R. et al. Functional enhancers shape extrachromosomal oncogene amplifications. Cell 179, 1330–1341.e13 (2019).
Wu, S. et al. Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature 575, 699–703 (2019).
Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science 362, eaav1898 (2018).
Helmsauer, K. et al. Enhancer hijacking determines intra- and extrachromosomal circular MYCN amplicon architecture in neuroblastoma. Preprint at bioRxiv https://doi.org/10.1101/2019.12.20.875807 (2019).
Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).
Hadi, K. et al. Novel patterns of complex structural variation revealed across thousands of cancer genome graphs. Preprint at bioRxiv https://doi.org/10.1101/836296 (2019).
Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210–216 (2019).
Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676–689.e3 (2018).
Hu, X. et al. TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Res. 46, D1144–D1149 (2018).
Yoshihara, K. et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene 34, 4845–4854 (2015).
Torres-García, W. et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30, 2224–2226 (2014).
Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581–591 (2018).
Quinlan, A. R. BEDTools: the Swiss-army tool for genome feature analysis. Curr. Protoc. Bioinformatics 47, 11.12.1–11.12.34 (2014).
This work was supported by the Ludwig Institute for Cancer Research (P.S.M.), Defeat GBM Program of the National Brain Tumor Society (P.S.M.), NVIDIA Foundation, Compute for the Cure (P.S.M.), Ben and Catherine Ivy Foundation (P.S.M.), generous donations from the Ziering Family Foundation in memory of Sigi Ziering (P.S.M.) and Ruth L. Kirschstein National Research Service Award. This work was also supported by the following National Institutes of Health grants: NS73831 (to P.S.M.), GM114362 (to V.B.), R01 CA190121, R01 CA237208 and R21 NS114873. This work was supported by Cancer Center Support Grant P30 CA034196 (R.G.W.V), grant nos. R35CA209919 (to H.Y.C.) and RM1-HG007735 (to H.Y.C.), R35GM133600 (to C.R.B.), National Science Foundation grant nos. NSF-IIS-1318386 and NSF-DBI-1458557 (to V.B.), and grants from the Musella Foundation, B*CURED Foundation, Brain Tumour Charity and Department of Defense grant no. W81XWH1910246 (to R.G.W.V). H.Y.C. is an Investigator of the Howard Hughes Medical Institute. The results published in this paper are in whole or part based on data generated by the TCGA Research Network (https://www.cancer.gov/tcga) and the International Cancer Genome Consortium (https://icgc.org/). Analysis of the TCGA and International Cancer Genome Consortium datasets was made possible through the Cancer Genomics Cloud of the Institute for Systems Biology (ISB-CGC) and the Amazon Web Services Cloud, respectively.
H.Y.C., P.S.M., V.B. and R.G.W.V. are scientific cofounders of Boundless Bio and serve as consultants. V.B. is a cofounder and has equity interest in Digital Proteomics, and receives income from Digital Proteomics. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. N.P.N. and K.T. are employees of Boundless Bio.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
a. Validation on cell line data. Validation of the classification scheme on cell line data with FISH experiments for detecting ecDNA from the Turner et al. and deCarvalho et al. studies, in addition to newly generated data. FISH probes were designed for selected oncogenes and DAPI staining was performed to determine whether the FISH probe landed on chromosomal DNA or ecDNA. For each cell (represented as an image of the cell in metaphase), the number of positive ecDNA probes were counted, and for each cell line, the average positive ecDNA per cell was reported. For each probe, we report whether it landed in an amplicon (inferred from AmpliconArchitect), and if so, what was the amplicon’s classification. The distribution for the average ecDNA per cell between the Circular and non-circular classes was statistically significantly different (p-value < 1e-9; Wilcoxon rank sum test). b–d. Whole-genome sequencing derived based Circular amplicon regions (blue) were validated with Circle-seq (red) for three neuroblastoma samples (CB2001, CB2022, and CB2050, respectively) used in the Koche et al. study.
a. 24 recurrently amplified oncogenes significantly overlap circular regions (z-score 37.8), especially compared to amplified non-circular regions (z-scores of 30.4, 29.5, 28.0 for Linear, Heavily-rearranged, and BFB). b. For all oncogenes on amplicons with copy number >= 4 and present in at least 5 samples across the cohort, we show the class distribution of that oncogene. The oncogenes are ordered by proportion on circular amplification. c. For the 24 recurrent oncogenes known to be activated via amplification (Zack et al. Nat Gen. 2013), we report the average copy number for the oncogenes for circular amplification versus amplified-noncircular amplification. d. Breakpoint location across all samples for each recurrently amplified oncogene. We identified all breakpoints from each sample containing the recurrent oncogene on ecDNA and report the total number of breakpoints across this region in 1kb binned windows. e. Distribution of breakpoint locations across all circular samples for each recurrently amplified oncogene. We identified all breakpoints from each sample containing the recurrent oncogene on ecDNA. Shown is the distribution of the number of breakpoints in each bin, which closely follows a Poisson distribution, suggesting that the breakpoints are mostly randomly distributed across the region.
a. Chromosome arm aneuploidy scores showing no or marginal difference in chromosomal arm level events between circular and non-circular amplification classes. b. Genome doubling events by amplification class. c. Distribution for total DNA loss segments by amplification class. WGS-inferred CNV data was used to count the total number of DNA losses within a sample. A DNA loss was defined as a segment with CN < 2. d. Distribution for total DNA gain segments by amplification class. WGS-inferred CNV data was used to count the total number of DNA gains within a sample. A DNA gain was defined as a segment with CN > 2. Circular samples contain statistically significantly more DNA gains than BFB, Heavily-rearranged, Linear, and No-fSCNA (p-value <0.03, <0.03, <1e-20, and <1e-111, respectively; Wilcox Rank Sum Test). e. Breakpoint homology by amplification class. f. Comparison of amplicon versus locus-level chromothripsis (Pearson’s Chi-squared test data: X-squared = 4674.7, df = 3, p-value < 2.2e-16). g. Comparison of sample category versus sample-level chromothripsis (Pearson’s Chi-squared test data: X-squared = 21.58, df = 3, p-value 8e-05 (excludes ‘No fSCNA detected’ category)). h. Comparison of sample category versus sample-level tandem duplication (Pearson’s Chi-squared test data: X-squared = 7.39, df = 3, p-value 0.06 (excludes ‘No fSCNA detected’ category)).
Copy number of the oncogene versus its fold-change in FPKM for all oncogenes with a copy count greater than 4, for each oncogene on each amplicon. The fold-change in FPKM is computed as the oncogene’s (FPKM-UQ+1) divided by the average of (FPKM-UQ+1) for the same oncogene in all other tumor samples from the same cohort for which the oncogene is not on any amplicon (that is, not amplified). Linear regression lines, using fold change = m*CNV+b where m and b are selected to minimize error of the fit, are shown for each class. Tukey’s range test shows oncogenes on circular structures are significantly different to oncogenes on non-circular structures (p-value < 1e-7).
Lymph node stage for primary tumors showing samples with amplification are more likely to have spread to the lymph node at time of diagnosis (Chi-square test; df=4; p-value<1e−05).
Extended Data Fig. 6 Cell cycle and immune infiltrate gene expression signatures vs amplicon classes.
a. Cell Cycle gene expression signature single sample GSEA (ssGSEA) scores by amplification category. b. Immune infiltrate gene expression signature single sample GSEA (ssGSEA) scores by amplification category.
About this article
Cite this article
Kim, H., Nguyen, NP., Turner, K. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet 52, 891–897 (2020). https://doi.org/10.1038/s41588-020-0678-2
This article is cited by
Deciphering the role of extrachromosomal circular DNA in adipose stem cells from old and young donors
Stem Cell Research & Therapy (2023)
A distinct circular DNA profile intersects with proteome changes in the genotoxic stress-related hSOD1G93A model of ALS
Cell & Bioscience (2023)
Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9
Genome Medicine (2023)
BMC Cancer (2023)
Epigenetics & Chromatin (2023)